David van Veenhuyzen
- Molecular Medicine top 2%
- Pharmacology top 5%
- Epidemiology
- Applied Microbiology and Biotechnology top 2%
- Molecular Biology
- Co-authors
- Simon PortsmouthRoger EcholsMitsuaki MachidaJuan Camilo Arjona FerreiraMari AriyasuTsutae Den NagataPéter TenkeWilhelm Haverkamp
- Topics
- Antibiotics Pharmacokinetics and Efficacy (4 papers)Prostate Cancer Treatment and Research (3 papers)Urinary Tract Infections Management (2 papers)
- Journals
- Journal of Clinical OncologyInternational Journal of Radiation Oncology*Biology*PhysicsThe Lancet Infectious Diseases
- Partner nations
- United StatesJapanFrance
In The Last Decade
David van Veenhuyzen
6 papers receiving 381 citations
Hit Papers
Peers
Comparison fields: 5 of 65
- Molecular Medicine 254
- Pharmacology 208
- Epidemiology 130
- Applied Microbiology and Biotechnology 121
- Molecular Biology 40
Countries citing papers authored by David van Veenhuyzen
This map shows the geographic impact of David van Veenhuyzen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David van Veenhuyzen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David van Veenhuyzen more than expected).
Fields of papers citing papers by David van Veenhuyzen
This network shows the impact of papers produced by David van Veenhuyzen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David van Veenhuyzen. The network helps show where David van Veenhuyzen may publish in the future.
Co-authorship network of co-authors of David van Veenhuyzen
This figure shows the co-authorship network connecting the top 25 collaborators of David van Veenhuyzen. A scholar is included among the top collaborators of David van Veenhuyzen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David van Veenhuyzen. David van Veenhuyzen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 4 | |
| 4 | Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trialbreakdown → | 305 |
| 5 | 24 | |
| 6 | 36 | |
| 7 | 22 |
About David van Veenhuyzen
David van Veenhuyzen is a scholar working on Pharmacology, Otorhinolaryngology and Molecular Medicine, having authored 7 papers that have together received 392 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (4 papers), Prostate Cancer Treatment and Research (3 papers) and Urinary Tract Infections Management (2 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (121 citations), Molecular Medicine (254 citations) and Pharmacology (208 citations). David van Veenhuyzen has collaborated with scholars based in United States, Japan and France. Frequent co-authors include Simon Portsmouth, Roger Echols, Mitsuaki Machida, Juan Camilo Arjona Ferreira, Mari Ariyasu, Tsutae Den Nagata, Péter Tenke, Wilhelm Haverkamp, Pierre Arvis and Martin Desrosiers. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and The Lancet Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.